Latest news with #S&PBSE500
&w=3840&q=100)
Business Standard
03-07-2025
- Business
- Business Standard
Nykaa shares slide 5% after multiple large trades; check likely seller here
Shares of FSN E-commerce -- the parent company of Nykaa -- slipped nearly 5 per cent in trade on Thursday after about 65.3 million shares changed hands in multiple block deals. The E-commerce firm's stock fell as much as 4.77 per cent during the day to ₹201.5 per share, the steepest intraday fall since June 2 this year. The stock pared some losses to trade 4.1 per cent lower at ₹202.5 apiece, compared to a 0.23 per cent advance in Nifty 50 as of 9:45 AM. Shares of the company are up over 5 per cent from its recent lows of ₹192, which it hit last month, and have recovered over 25 per cent from April lows. The counter has risen 24 per cent this year, compared to a 7.6 per cent advance in the benchmark Nifty 50. FSN E-commerce has a total market capitalisation of ₹57,980.34 crore, according to BSE data. Track LIVE Stock Market Updates Here Nykaa block deal The shares took a plunge after about 65.3 million shares, or a 2.3 per cent stake, changed hands in three block trades during market opening, according to Bloomberg. The buyers and sellers were not known immediately. However, the news agency earlier reported that Harindarpal Singh Banga and Indra Banga are offering to raise up to ₹1,200 crore via a sale of shares. The floor price for the transaction was set at ₹200 per share, a discount of ₹11 compared with Wednesday's close on NSE. Goldman Sachs and JP Morgan are managing the deal, the report added. Harindarpal Singh Banga had about 4.97 per cent stake in the company as of the March 2025 quarter, according to BSE data. The stock of Nykaa was the most-traded stock by volume and value, according to Bloomberg. It was the worst performer on the S&P BSE 500, Nifty Midcap 100 indexes. The trading volume was above 7.8 times the three-month full-day average. Nykaa Q4 results The online beauty retailer released its Q4 results on Friday, after market hours. In its fourth quarter ended March 31, 2025, the company reported a 193 per cent rise in consolidated net profit at ₹20.28 crore for Q4FY25, compared to ₹6.93 crore in the year-ago period. Its revenue from operations also jumped 23.6 per cent year-on-year (Y-o-Y) to ₹2,062 crore in Q4FY25, from ₹1,668 crore in Q4FY24. Nykaa's earnings before interest, taxes, depreciation, and amortisation (Ebitda) for the quarter expanded 43 per cent YoY to ₹133 crore. The company's gross merchandise value (GMV) also increased 27 per cent YoY to ₹4,102 crore in Q4FY25.
Business Standard
25-06-2025
- Business
- Business Standard
Concord Biotech edges higher on value buying; trades above 100-day SMA
Concord Biotech advanced 1.56% to Rs 1808.55 as value buying emerged at lower level. The scrip had declined 15.63% in seven sessions to end at Rs 1,780.75 yesterday, from its recent closing high of Rs 2,110.55 recorded on 13 June 2025. On a year-to-date (YTD) basis, the stock has fallen by 15.13% while the S&P BSE Sensex and the S&P BSE 500 index have gained 5.10% and 3.15%, respectively. On the technical front, the stocks RSI (14) was currently at 47.428. An RSI reading of 70 or above indicates an overbought condition. A reading of 30 or below indicates an oversold condition. On the daily chart, the scrip is trading below its 10-day and 20-day simple moving averages (SMAs) placed at 1959.50 and 1928.23, respectively. It is, however, trading above 100-day SMA positioned at 1750.69. In a regulatory filing made yesterday, Concord Biotech said that it has received an establishment inspection report (EIR) from the US Food and Drug Administration (US FDA) for the inspection carried out by them at its API facility at Dholka from 28 April 2025 till 2 May 2025. It further said that the USFDA has officially concluded its inspection, which is now closed under 21 CFR 20.64(d)(3). "This closure indicates that no regulatory action is required, and the facility is permitted to continue its operations without any restrictions, Concord Biotech stated. Concord Biotech is involved in manufacturing fermentation and semi-synthetic biopharmaceutical APIs with immunosuppressants as its key therapeutic segment.
